• PX-478 in Prenatal Hypoxia–Related ASD

  2026-08-25

  A 2024 rat study found that postnatal PX-478 treatment reduced autism-like behaviors and hippocampal neuronal necrosis after prenatal hypoxia, while altering HIF-1α, PTEN, and VEGF-related readouts. The work positions HIF-1α inhibition as a mechanistic probe in prenatal hypoxia models, but its timing-dependent safety findings and lack of direct causal assays limit immediate translation.

• DNase I (RNase-free) for RNA Workflows

  2026-08-24

  Improve RNA extraction, RT-PCR, and in vitro transcription sample preparation by removing DNA without introducing RNase activity. This guide also shows how cation selection and cleanup design can support chromatin and RNA vaccine workflows.

• Penicillin G Sodium in Reliable Cell Assays

  2026-08-23

  Learn how Penicillin G Sodium (SKU B1678) can support contamination-aware cell viability, proliferation, and cytotoxicity workflows without confusing antimicrobial activity with mammalian-cell effects. This scenario-based guide covers assay compatibility, preparation, interpretation, and evidence-based product selection.

• Maridomycin: In Vitro and In Vivo Activity

  2026-08-22

  Kondo and colleagues characterized maridomycin through a linked series of antimicrobial, resistance, pharmacological, and mouse infection experiments. The study established strong activity against many Gram-positive organisms, identified important assay-dependent effects, documented cross-resistance with macrolides, and showed therapeutic efficacy comparable to leucomycin in selected murine infections.

• 4-MUG: A Decision Tool for Gaucher Translation

  2026-08-21

  4-Methylumbelliferyl-β-D-Glucopyranoside converts glucosidase activity into a sensitive fluorescent endpoint, creating a practical bridge between GCase biology, mRNA engineering, and Gaucher disease translation. This article explains how to use 4-MUG strategically rather than treating it as merely another fluorogenic substrate.

• SP600125: From JNK Mechanism to Translational Strategy

  2026-08-21

  SP600125 offers a practical way to interrogate JNK–c-Jun signaling while building a translational bridge between inflammation, apoptosis, cancer research, and radiation-induced neural differentiation. This article turns biochemical potency into an evidence-led experimental strategy, while separating established findings from testable hypotheses.

• 6-FAM SE: Durable Labeling Workflows

  2026-08-20

  6-FAM SE provides an amine-reactive route to durable fluorescent conjugates for oligonucleotides, proteins, peptides, and assay development. This guide connects practical labeling chemistry with nanoparticle tracking concepts inspired by a melanoma photothermal-immunotherapy study, while clearly separating established product properties from workflow recommendations.

• 0.4% Trypan Blue Solution: Practical Workflow

  2026-08-20

  0.4% Trypan Blue Solution provides a direct membrane-integrity readout for cell viability measurement and live/dead cell discrimination in cultured-cell workflows. It is suitable for research cell counting and cytotoxicity assays, but not for clinical diagnosis or for resolving apoptosis from necrosis.

• Broad-Spectrum Bivalent mRNA Vaccine: Preclinical Evidence

  2026-08-19

  The reference study evaluates RQ3025, a bivalent mRNA vaccine designed around shared spike mutations from diverse SARS-CoV-2 evolutionary lineages. Across mouse, hamster, and rat models, the vaccine generated broad neutralizing responses, showed protection against several emerging variants, induced a Th1-biased cellular response, and produced no apparent organ pathology at a high tested dose.

• Cyclic Pifithrin-α Hydrobromide: p53 Inhibitor

  2026-08-19

  Cyclic Pifithrin-α hydrobromide is a research-use p53 inhibitor that blocks p53-dependent gene transactivation. Its reported applications include apoptosis inhibition in cancer research, DNA-damage response studies, and protection from gamma irradiation in mice, but it is not a clinical radioprotective or anticancer treatment.

• Concanamycin A: V-ATPase Workflow Guide

  2026-08-18

  Concanamycin A enables controlled disruption of lysosomal proton transport to separate acidification-dependent adaptation from terminal cancer-cell injury. This guide translates V-ATPase inhibition into practical workflows for metabolic-stress signaling, apoptosis, trafficking, and prostate cancer cell invasion inhibition, with troubleshooting guidance for reproducible assays.

• 1-myristoylglycerophosphocholine: From Lipidomics to Assays

  2026-08-18

  Explore how 1-myristoylglycerophosphocholine, also called 14:0 Lyso-PC, can translate lipidomics findings into better fibrosis and smooth muscle assays. This guide emphasizes species-level controls, source-to-target biology, and practical reagent handling.

• Isradipine (Dynacirc): From Channels to Translation

  2026-08-17

  A mechanistic and strategic guide to using Isradipine (Dynacirc) in neurovascular, hypertension, and neurodegenerative disease research, with emphasis on channel selectivity, experimental controls, and translational interpretation.

• Pretomanid and Terminal Oxidases in Tuberculosis

  2026-08-16

  The reference study identifies the cytochrome bcc:aa3 and cytochrome bd oxidases as respiratory targets of pretomanid, clarifying how this nitroimidazole prodrug acts against both replicating and antibiotic-tolerant Mycobacterium tuberculosis. Its combination data support rational regimens using complementary terminal-oxidase inhibitors to increase bactericidal activity and limit resistance emergence.

• 7-Ethyl-10-hydroxycamptothecin: Assay Workflows

  2026-08-15

  Build reproducible colon cancer assays around 7-Ethyl-10-hydroxycamptothecin, from DMSO formulation through cell-cycle and apoptosis readouts. The workflow also incorporates SN-38-driven FUBP1–FUSE research to distinguish topoisomerase I inhibition from complementary transcriptional effects.

453 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page